日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Insight into the mechanism of action of ORG27569 at the cannabinoid type one receptor utilising a unified mathematical model

利用统一数学模型深入了解 ORG27569 对大麻素一型受体的作用机制

Hayley M Green, Liang Yang, Xiao Zhu, David B Finlay, Stephen B Duffull, Michelle Glass

Determination of the Cannabinoid CB1 Receptor's Positive Allosteric Modulator Binding Site through Mutagenesis Studies

通过诱变研究确定大麻素 CB1 受体的正变构调节剂结合位点

Hayley M Green, Daniel M J Fellner, David B Finlay, Daniel P Furkert, Michelle Glass

Cannabinoid 1 (CB1 ) receptor arrestin subtype-selectivity and phosphorylation dependence

大麻素1(CB1)受体阻遏蛋白亚型选择性和磷酸化依赖性

Jamie J Manning ,Gabriel Rawcliffe ,David B Finlay ,Michelle Glass

The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism

哌嗪类似物对氟苯基哌嗪改变了合成大麻素受体激动剂 AMB-FUBINACA 的生理效应的时间,但不改变其鉴别刺激、信号传导效应或代谢

David B Finlay, Warwick Mackie, Hunter D J Webb, Lucy R Thomsen, Mhairi Nimick, Rhonda J Rosengren, Julie A Marusich, Michelle Glass, Jenny L Wiley

Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor

评估合成大麻素受体激动剂在CB2受体上的信号偏向性

Monica Patel ,Natasha L Grimsey ,Samuel D Banister ,David B Finlay ,Michelle Glass

Characterisation of AMB-FUBINACA metabolism and CB1-mediated activity of its acid metabolite

AMB-FUBINACA 代谢的特征及其酸性代谢物的 CB1 介导活性

Hunter D J Webb, David B Finlay, Shuli Chen, Andrea J Vernall, Eric Sparkes, Samuel D Banister, Rhonda J Rosengren, Michelle Glass

Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors; β-arrestins and GPCR kinases

阐明大麻素 CB2 受体与其调节效应因子(β-arrestin 和 GPCR 激酶)之间的相互作用

Monica Patel ,Christoph Matti ,Natasha L Grimsey ,Daniel F Legler ,Jonathan A Javitch ,David B Finlay ,Michelle Glass

In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1 H-indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator?

6-甲基-3-(2-硝基-1-(噻吩-2-基)乙基)-2-苯基-1H-吲哚 (ZCZ011) 在 1 型大麻素受体上的体外表征:变构激动剂还是变构调节剂?

Hayley M Green ,David B Finlay ,Ruth A Ross ,Iain R Greig ,Stephen B Duffull ,Michelle Glass

Correction: The american pediatric society and society for pediatric research joint statement against racism and social injustice

更正:美国儿科学会和儿科研究学会联合发表反对种族主义和社会不公正的声明

Abman, Steven H; Armstrong, Sarah; Baker, Susan; Bogue, Clifford W; Carlo, Waldemar; Chalak, Lina; Daniels, Stephen R; Davis, Stephanie; Debaun, Michael R; Fike, Candice; Frazer, Lauren; Gibson, Keisha; Gill, Michelle; Glass, Hannah; Gordon, Catherine M; Goyal, Monika; Hirschhorn, Joel; Holtz, Lori; Hunstad, David A; Leonard, Mary B; Maitre, Nathalie; Markham, Larry; McAllister-Lucas, Linda; Orange, Jordan; Shah, Prachi; Simon, Tamara; Steinhorn, Robin H; Tarini, Beth; Walker-Harding, Leslie R

A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models

大麻素 CB1 受体的新型变构调节剂可改善啮齿动物模型中的多巴胺能亢进内表型

Catharine A Mielnik, Kim S Sugamori, David B Finlay, Hayley H A Thorpe, Matthieu Schapira, Nirunthan Sivananthan, Chun Kit Li, Vincent M Lam, Sean Harrington, Mostafa H Abdelrahman, Laurent A Trembleau, W McIntyre Burnham, Jibran Y Khokhar, Ali Salahpour, Amy J Ramsey, Michelle Glass, Iain R Greig,